TOP Investment Portfolio Adriakaim Inc.
Life Science & Agritech

Adriakaim Inc.

Representative Director Masatoshi Kobayashi
Adriakaim Inc.
We will innovate treatments for acute myocardial infarction patients by developing treatment devices that put people first.


Adriakaim Inc. is a venture company that aims to increase the healthy life expectancies of patients with mid- to severe cases of acute myocardial infarction. This is done by providing treatment device systems that focus on the autonomous nerve functions to maximize the natural healing power of the human body.

Due to the growing senior population, the number of chronic heart failure patients and expensive medical costs associated therewith have grown significantly, causing a major social issue worldwide.
Today, advanced catheter treatment technologies can, fortunately, save the lives of many acute myocardial infarction patients, who likely would not have survived 10 or 20 years ago.
Nevertheless, there are still many cases with poor prognoses and approximately 30% of patients develop severe chronic heart failure even with the use of the latest treatment medications. Adriakaim’s technologies aim to improve the symptoms of such patients and extend their healthy life expectancies.


We will be Adriakaim is a startup that has spun out of a major medical device medical equipment company. When the company decided to withdraw from the cardiovascular field, the development members at the time held discussions with relevant parties and purchased the technology assets from the company. They then established Adriakaim Inc. in November 2018.
As a company strategy, we decided to withdraw from the cardiovascular field.
The development members at that time had discussions and purchased a patent in November 2018 to establish " Adriakaim Inc."


Adriakaim has the following three competitive advantages.
● The world's first technology for acute myocardial infarction from the National Cerebral and Cardiovascular Center.
● It is a spin-out startup from a large company with the advantages of holding patents and strong manufacturing capabilities.
● The stray nerve stimulation technology is a new technology that is anticipated to be further developed and applied in different fields.

Room 101 Hachioji Seni Center Building ,13-1 Minami Shin-cho , Hachioji-shi , Tokyo , Japan


Sign up for UTokyo IPC news